{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:09:13Z","timestamp":1788480553434,"version":"build-2803163510"},"reference-count":190,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cjca.2026.01.055","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T07:57:23Z","timestamp":1770191843000},"page":"1018-1039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Gene-based Therapies for Genetic Cardiomyopathies: Molecular Medicine for Heart Disease"],"prefix":"10.1016","volume":"42","author":[{"given":"Shubham","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandu","family":"Sadasivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-9028","authenticated-orcid":false,"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.01.055_bib1","first-page":"547","article-title":"Cardiomyopathies and genetic testing in heart failure: role in defining phenotype-targeted approaches and management","volume":"37","author":"Yogasundaram","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib2","first-page":"2312","article-title":"Canadian Cardiovascular Society clinical practice update on cardiogenetic testing","volume":"41","author":"Care","year":"2025","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3516","article-title":"State of the art and perspectives of gene therapy in heart failure. A scientific statement of the Heart Failure Association of the ESC, the ESC Council on Cardiovascular Genomics and the ESC Working Group on Myocardial & Pericardial Diseases","volume":"27","author":"Van Linthout","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.055_bib4","first-page":"e471","article-title":"Gene therapy in cardiovascular disease: recent advances and future directions in science: a science advisory from the American Heart Association","volume":"150","author":"Kim","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(23)01241-2","article-title":"Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches","volume":"402","author":"Heymans","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.01.055_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","article-title":"Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine","volume":"22","author":"Gigli","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib8","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.122.320496","article-title":"CRISPR modeling and correction of cardiovascular disease","volume":"130","author":"Liu","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014345","article-title":"Exosomes from induced pluripotent stem cell-derived cardiomyocytes promote autophagy for myocardial repair","volume":"9","author":"Santoso","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2026.01.055_bib10","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1093\/cvr\/cvab335","article-title":"Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration","volume":"118","author":"Hunkler","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-0716-0668-1_21","article-title":"In vitro synthesis of modified RNA for cardiac gene therapy","volume":"2158","author":"Sultana","year":"2021","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib12","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/cvr\/cvaf109","article-title":"Gene therapy in cardiac and vascular diseases: a review of approaches to treat genetic and common cardiovascular diseases with novel gene-based therapeutics","volume":"121","author":"Musolino","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s43856-023-00419-1","article-title":"Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders","volume":"4","author":"Lauffer","year":"2024","journal-title":"Commun Med (Lond)"},{"key":"10.1016\/j.cjca.2026.01.055_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102636","article-title":"Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges","volume":"36","author":"Kalter","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chembiol.2025.05.003","article-title":"Charting the development and engineering of CRISPR base editors: lessons and inspirations","volume":"32","author":"Zou","year":"2025","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib16","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ymthe.2020.07.021","article-title":"Current status and challenges of DNA base editing tools","volume":"28","author":"Jeong","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib17","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/cpmb.129","article-title":"Base editing in human cells to produce single-nucleotide-variant clonal cell lines","volume":"133","author":"Vasquez","year":"2020","journal-title":"Curr Protoc Mol Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41434-020-0171-7","article-title":"Investigation of the safety and feasibility of AAV1\/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL","volume":"27","author":"Lyon","year":"2020","journal-title":"Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib20","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1038\/s41591-025-04011-z","article-title":"Cardiotropic AAV gene therapy for heart failure: a phase 1 trial","volume":"31","author":"Henry","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib21","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","article-title":"First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1","volume":"121","author":"Desai","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib22","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models","volume":"16","author":"Greer-Short","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.01.055_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41587-023-01758-z","article-title":"Efficient prime editing in mouse brain, liver and heart with dual AAVs","volume":"42","author":"Davis","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.cjca.2026.01.055_bib26","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ymthe.2021.09.002","article-title":"In vivo somatic cell base editing and prime editing","volume":"29","author":"Newby","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib27","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JND-221639","article-title":"Meeting report: 2022 Muscular Dystrophy Association summit on \u2018Safety and Challenges in Gene Transfer Therapy","volume":"10","author":"Lek","year":"2023","journal-title":"\u2019 J Neuromuscul Dis"},{"key":"10.1016\/j.cjca.2026.01.055_bib29","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Re: \u201cMoving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy\u201d by Wilson and Flotte","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib30","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis confirms deaths of two patients treated with gene therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib31","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.cjca.2026.01.055_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib33","doi-asserted-by":"crossref","unstructured":"Argueta Portillo CS, Landstrom AP. A primer on cardiovascular gene therapy for the practitioner: what clinicians need to know [e-pub ahead of print]. Can J Cardiol https:\/\/doi.org\/10.1016\/j.cjca.2025.11.034.","DOI":"10.1016\/j.cjca.2025.11.034"},{"key":"10.1016\/j.cjca.2026.01.055_bib34","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jchf.2023.09.015","article-title":"Applications of gene therapy in cardiomyopathies","volume":"12","author":"Argiro","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.055_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102457","article-title":"Advanced delivery systems for gene editing: a comprehensive review from the GenE-HumDi COST Action Working Group","volume":"36","author":"Cavazza","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib38","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jacbts.2022.04.002","article-title":"Cardiac transduction in mini-pigs after low-dose retrograde coronary sinus infusion of AAV9-BAG3","volume":"7","author":"Myers","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib39","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/s41598-024-51712-5","article-title":"Cardiac vein retroinjections provide an efficient approach for global left ventricular gene transfer with adenovirus and adeno-associated virus","volume":"14","author":"Lampela","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.cjca.2026.01.055_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54635-x","article-title":"AAV delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine","volume":"15","author":"Mazurek","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib41","doi-asserted-by":"crossref","first-page":"e1239","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.hrthm.2011.05.020","article-title":"HRS\/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)","volume":"8","author":"Ackerman","year":"2011","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.055_bib43","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/s41436-019-0521-2","article-title":"Correction: genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"21","author":"Hershberger","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.yjmcc.2011.01.014","article-title":"Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities","volume":"50","author":"Schlossarek","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib45","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.amjcard.2023.10.032","article-title":"Genetic testing in hypertrophic cardiomyopathy","volume":"212","author":"Ireland","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib46","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/CIRCHEARTFAILURE.111.963702","article-title":"Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function","volume":"5","author":"van Dijk","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.055_bib47","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1093\/eurheartj\/ehad372","article-title":"Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy","volume":"44","author":"Allouba","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.055_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax0069","article-title":"The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin","volume":"6","author":"Sarkar","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.cjca.2026.01.055_bib49","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10974-011-9268-3","article-title":"How do MYBPC3 mutations cause hypertrophic cardiomyopathy?","volume":"33","author":"Marston","year":"2012","journal-title":"J Muscle Res Cell Motil"},{"key":"10.1016\/j.cjca.2026.01.055_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00424-013-1409-7","article-title":"MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction","volume":"466","author":"Behrens-Gawlik","year":"2014","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.cjca.2026.01.055_bib51","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cvr\/cvae207","article-title":"Gene therapy for cardiac diseases: methods, challenges, and future directions","volume":"120","author":"Grisorio","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib52","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/jamacardio.2017.2352","article-title":"Role of genetic testing in inherited cardiovascular disease: a review","volume":"2","author":"Cirino","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib53","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s10038-007-0184-8","article-title":"Danon disease presenting with dilated cardiomyopathy and a complex phenotype","volume":"52","author":"Taylor","year":"2007","journal-title":"J Hum Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib54","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.omtn.2017.05.008","article-title":"Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes","volume":"7","author":"Prondzynski","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib55","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1038\/ncomms6515","article-title":"Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice","volume":"5","author":"Mearini","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib56","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice","volume":"29","author":"Chai","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib57","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.omtn.2020.01.012","article-title":"Allele-selective knockdown of MYH7 using antisense oligonucleotides","volume":"19","author":"Anderson","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib58","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax1744","article-title":"Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease","volume":"12","author":"Manso","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib59","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/hrt.2003.029504","article-title":"Danon\u2019s disease as a cause of hypertrophic cardiomyopathy: a systematic survey","volume":"90","author":"Charron","year":"2004","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2026.01.055_bib60","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1056\/NEJMoa2412392","article-title":"Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease","volume":"392","author":"Greenberg","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib61","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11940-022-00736-1","article-title":"Pompe disease: a clinical, diagnostic, and therapeutic overview","volume":"24","author":"Stevens","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib62","first-page":"883","article-title":"Clinical features, diagnosis, and management of patients with Anderson-Fabry cardiomyopathy","volume":"33","author":"Yogasundaram","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313147","article-title":"Unveiling the future of cardiac care: a review of gene therapy in cardiomyopathies","volume":"25","author":"Venturiello","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib65","first-page":"777","article-title":"Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?","volume":"40","author":"Paratz","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib66","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.1236921","article-title":"Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy","volume":"342","author":"Jiang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cjca.2026.01.055_bib67","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.omtn.2021.12.039","article-title":"Programmable siRNA pro-drugs that activate RNAi activity in response to specific cellular RNA biomarkers","volume":"27","author":"Han","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib68","doi-asserted-by":"crossref","first-page":"8374","DOI":"10.1128\/MCB.24.19.8374-8385.2004","article-title":"Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5","volume":"24","author":"Vega","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib69","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/emmm.201202168","article-title":"Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice","volume":"5","author":"Gedicke-Hornung","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib72","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I study of liver depot gene therapy in late-onset Pompe disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib73","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib74","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"37","author":"Pinto","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.055_bib75","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","article-title":"Evidence-based assessment of genes in dilated cardiomyopathy","volume":"144","author":"Jordan","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib76","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.055_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1296389","article-title":"Comprehensive review on gene mutations contributing to dilated cardiomyopathy","volume":"10","author":"Wang","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111460","article-title":"Dilated cardiomyopathy: a genetic journey from past to future","volume":"25","author":"Newman","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib79","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMoa1110186","article-title":"Truncations of titin causing dilated cardiomyopathy","volume":"366","author":"Herman","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib80","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4070\/kcj.2021.0154","article-title":"Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure","volume":"51","author":"Kim","year":"2021","journal-title":"Korean Circ J"},{"key":"10.1016\/j.cjca.2026.01.055_bib81","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1038\/s41467-021-23272-z","article-title":"Cardiomyocyte contractile impairment in heart failure results from reduced BAG3-mediated sarcomeric protein turnover","volume":"12","author":"Martin","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib82","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1083\/jcb.200811035","article-title":"Lamin A\/C-mediated neuromuscular junction defects in Emery-Dreifuss muscular dystrophy","volume":"184","author":"M\u00e9jat","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib83","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrm1151","article-title":"Phospholamban: a crucial regulator of cardiac contractility","volume":"4","author":"MacLennan","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib84","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1517\/14712590903321462","article-title":"Sarcoplasmic reticulum Ca2+ ATPase as a therapeutic target for heart failure","volume":"10","author":"Lipskaia","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib85","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCRESAHA.123.323053","article-title":"Unleashing the power of genetics: PLN ablation, phospholambanopathies and evolving challenges","volume":"134","author":"Mattiazzi","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012661","article-title":"Unraveling the pathophysiological mechanisms of phospholamban R14del cardiomyopathy: a comprehensive overview","volume":"18","author":"Maas","year":"2025","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.055_bib87","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCRESAHA.118.314014","article-title":"PLN Foundation","volume":"123","author":"Kranias","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib88","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacbts.2024.02.017","article-title":"Reassessing the mechanisms of PLN-R14del cardiomyopathy: from calcium dysregulation to S\/ER malformation","volume":"9","author":"Stege","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib89","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s12471-013-0401-3","article-title":"Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy","volume":"21","author":"van der Zwaag","year":"2013","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cjca.2026.01.055_bib90","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/CIRCRESAHA.119.313569","article-title":"Novel therapies for prevention and early treatment of cardiomyopathies","volume":"124","author":"Repetti","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib91","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.3390\/jcm9092770","article-title":"Modifications of titin contribute to the progression of cardiomyopathy and represent a therapeutic target for treatment of heart failure","volume":"9","author":"Tharp","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib92","series-title":"Exon skipping and inclusion therapies: methods and protocols","first-page":"53","article-title":"An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases","author":"Rodrigues","year":"2025"},{"key":"10.1016\/j.cjca.2026.01.055_bib93","doi-asserted-by":"crossref","first-page":"232","DOI":"10.31662\/jmaj.2021-0019","article-title":"Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy","volume":"4","author":"Matsuo","year":"2021","journal-title":"JMA J"},{"key":"10.1016\/j.cjca.2026.01.055_bib94","doi-asserted-by":"crossref","first-page":"562","DOI":"10.15252\/emmm.201505047","article-title":"Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy","volume":"7","author":"Gramlich","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib95","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.yjmcc.2019.04.014","article-title":"The assembly and evaluation of antisense oligonucleotides applied in exon skipping for titin-based mutations in dilated cardiomyopathy","volume":"131","author":"Hahn","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib96","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.119.039521","article-title":"Cronos titin is expressed in human cardiomyocytes and necessary for normal sarcomere function","volume":"140","author":"Zaunbrecher","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib97","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.123.063972","article-title":"CRISPR activation reverses haploinsufficiency and functional deficits caused by TTN truncation variants","volume":"149","author":"Ghahremani","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib98","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ade1633","article-title":"Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy","volume":"14","author":"Nishiyama","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib102","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1038\/s41467-021-24849-4","article-title":"Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy","volume":"12","author":"Chai","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib103","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jare.2025.01.001","article-title":"LMNA-related cardiomyopathy: from molecular pathology to cardiac gene therapy","volume":"77","author":"Wang","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib104","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/s12967-023-04542-4","article-title":"Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity","volume":"21","author":"Tan","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib105","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1038\/s41467-024-51318-5","article-title":"Lamin A\/C deficiency-mediated ROS elevation contributes to pathogenic phenotypes of dilated cardiomyopathy in iPSC model","volume":"15","author":"Qiu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib106","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1161\/CIRCULATIONAHA.123.065117","article-title":"Elimination of CaMKII\u03b4 autophosphorylation by CRISPR-Cas9 base editing improves survival and cardiac function in heart failure in mice","volume":"148","author":"Lebek","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib107","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175164","article-title":"CRISPR-Cas9 base editing of pathogenic CaMKII\u03b4 improves cardiac function in a humanized mouse model","volume":"134","author":"Lebek","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.cjca.2026.01.055_bib108","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","article-title":"In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice","volume":"589","author":"Koblan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2026.01.055_bib109","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41467-022-30800-y","article-title":"Transient expression of an adenine base editor corrects the Hutchinson-Gilford progeria syndrome mutation and improves the skin phenotype in mice","volume":"13","author":"Whisenant","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib110","article-title":"Adenine base editor-based correction of the cardiac pathogenic Lmna c.1621C > T mutation in murine hearts","volume":"28","author":"Yang","year":"2024","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib111","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.jacbts.2022.06.015","article-title":"Genetic ablation of the DNA damage response pathway attenuates lamin-associated dilated cardiomyopathy in mice","volume":"7","author":"Cheedipudi Sirisha","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib112","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jacbts.2022.09.002","article-title":"New insights into the therapy for lamin-associated dilated cardiomyopathy","volume":"7","author":"Zhang","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib113","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","article-title":"Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact","volume":"118","author":"Dave","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib114","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1093\/cvr\/cvaf156","article-title":"In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment","volume":"121","author":"Sun","year":"2025","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib115","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1038\/ncomms7955","article-title":"Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy","volume":"6","author":"Karakikes","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.cjca.2026.01.055_bib116","doi-asserted-by":"crossref","unstructured":"Chen ZY, Guo R, Wang M, et al. PLN-L31A\/I40A for the treatment of inherited heart disease caused by PLN-R14del mutations [e-pub ahead of print]. Acta Pharmacol Sin https:\/\/doi.org\/10.1038\/s41401-025-01711-7.","DOI":"10.1038\/s41401-025-01711-7"},{"key":"10.1016\/j.cjca.2026.01.055_bib117","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1038\/s41591-025-04002-0","article-title":"Cardiac gene therapy makes a comeback","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib121","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(02)07815-7","article-title":"The muscular dystrophies","volume":"359","author":"Emery","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2026.01.055_bib122","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2018.08.2182","article-title":"Cardiac phenotypes in hereditary muscle disorders: JACC State-of-the-Art Review","volume":"72","author":"Arbustini","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib123","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cjca.2026.01.055_bib124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population frequencies of inherited neuromuscular diseases\u2014a world survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2026.01.055_bib125","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014004","article-title":"Cardiac intervention improves heart disease and clinical outcomes in patients with muscular dystrophy in a multidisciplinary care setting","volume":"9","author":"Nikhanj","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cjca.2026.01.055_bib126","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr Physiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib127","first-page":"14","article-title":"Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies","volume":"15","author":"Le Rumeur","year":"2015","journal-title":"Bosn J Basic Med Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib128","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0969-2126(00)00132-5","article-title":"The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy","volume":"8","author":"Norwood","year":"2000","journal-title":"Structure"},{"key":"10.1016\/j.cjca.2026.01.055_bib129","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s42003-022-03980-y","article-title":"The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction","volume":"5","author":"Wilson","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.cjca.2026.01.055_bib130","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.nmd.2004.04.007","article-title":"Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings","volume":"14","author":"Quinlan","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2026.01.055_bib131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.yjmcc.2012.12.009","article-title":"Cardiac phenotype of Duchenne muscular dystrophy: insights from cellular studies","volume":"58","author":"Shirokova","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib132","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.3390\/jcm12144769","article-title":"Limb-girdle muscular dystrophies classification and therapies","volume":"12","author":"Bouchard","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib133","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/practneurol-2017-001799","article-title":"Making sense of the clinical spectrum of limb girdle muscular dystrophies","volume":"18","author":"Khadilkar","year":"2018","journal-title":"Pract Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib134","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s13311-018-0648-x","article-title":"The limb-girdle muscular dystrophies: is treatment on the horizon?","volume":"15","author":"Chu","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cjca.2026.01.055_bib135","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.nmd.2018.05.007","article-title":"229th ENMC international workshop: limb girdle muscular dystrophies - nomenclature and reformed classification Naarden, the Netherlands, 17-19 March 2017","volume":"28","author":"Straub","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2026.01.055_bib136","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00415-006-0213-0","article-title":"Cardiac involvement in limb-girdle muscular dystrophy 2I : conventional cardiac diagnostic and cardiovascular magnetic resonance","volume":"253","author":"Gaul","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib137","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2990.2004.00555.x","article-title":"Limb-girdle muscular dystrophies \u2013 from genetics to molecular pathology","volume":"30","author":"Laval","year":"2004","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib138","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41586-024-08310-2","article-title":"Structure and assembly of the dystrophin glycoprotein complex","volume":"637","author":"Wan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2026.01.055_bib139","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archneur.65.9.1196","article-title":"Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy","volume":"65","author":"Sveen","year":"2008","journal-title":"Arch Neurol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2026.01.055_bib140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jnc.12217","article-title":"Cardiomyopathy of Friedreich ataxia","volume":"126","author":"Weidemann","year":"2013","journal-title":"J Neurochem"},{"key":"10.1016\/j.cjca.2026.01.055_bib141","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2021.11.033","article-title":"Cellular pathophysiology of Friedreich\u2019s ataxia cardiomyopathy","volume":"346","author":"Lees","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib142","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2217\/nmt-2022-0011","article-title":"Friedreich ataxia: clinical features and new developments","volume":"12","author":"Keita","year":"2022","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.cjca.2026.01.055_bib143","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1089\/ars.2009.3015","article-title":"Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities","volume":"13","author":"Santos","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.cjca.2026.01.055_bib144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4330\/wjc.v11.i1.1","article-title":"Heart disease in Friedreich\u2019s ataxia","volume":"11","author":"Hanson","year":"2019","journal-title":"World J Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib145","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/0883073812448535","article-title":"Cardiomyopathy in Friedreich ataxia: clinical findings and research","volume":"27","author":"Payne","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib146","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacbts.2022.04.005","article-title":"Cardiovascular research in Friedreich ataxia","volume":"7","author":"Payne","year":"2022","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib147","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","article-title":"Mortality in Friedreich ataxia","volume":"307","author":"Tsou","year":"2011","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib148","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s10072-024-07826-9","article-title":"Myotonic dystrophies: an update on clinical features, molecular mechanisms, management, and gene therapy","volume":"46","author":"Rimoldi","year":"2025","journal-title":"Neurol Sci"},{"key":"10.1016\/j.cjca.2026.01.055_bib149","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.bbadis.2014.05.019","article-title":"Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms","volume":"1852","author":"Meola","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cjca.2026.01.055_bib150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(12)70204-1","article-title":"The myotonic dystrophies: molecular, clinical, and therapeutic challenges","volume":"11","author":"Udd","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib151","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrg1689","article-title":"Repeat instability: mechanisms of dynamic mutations","volume":"6","author":"Pearson","year":"2005","journal-title":"Nature Rev Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib152","first-page":"10","article-title":"Anticipation in myotonic dystrophy: new light on an old problem","volume":"51","author":"Harper","year":"1992","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib153","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1093\/nar\/gku767","article-title":"MBNL proteins and their target RNAs, interaction and splicing regulation","volume":"42","author":"Konieczny","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib154","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/hmg\/ddh327","article-title":"Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons","volume":"13","author":"Jiang","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib155","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1212\/01.WNL.0000147335.10783.E4","article-title":"Sudden cardiac death in myotonic dystrophy type 2","volume":"63","author":"Schoser","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.cjca.2026.01.055_bib156","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.nmd.2009.04.012","article-title":"Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: a case control study","volume":"19","author":"Wahbi","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2026.01.055_bib157","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/mus.26782","article-title":"Emery-Dreifuss muscular dystrophy","volume":"61","author":"Heller","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.cjca.2026.01.055_bib158","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.ejhg.5200744","article-title":"Emery-Dreifuss muscular dystrophy","volume":"10","author":"Helbling-Leclerc","year":"2002","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib159","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s100480050020","article-title":"Emerin, deficiency of which causes Emery-Dreifuss muscular dystrophy, is localized at the inner nuclear membrane","volume":"1","author":"Yorifuji","year":"1997","journal-title":"Neurogenetics"},{"key":"10.1016\/j.cjca.2026.01.055_bib160","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1016\/j.hrthm.2013.06.020","article-title":"Implantable cardioverter-defibrillators in lamin A\/C mutation carriers with cardiac conduction disorders","volume":"10","author":"Anselme","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.055_bib161","first-page":"155","article-title":"Chapter 12 \u2013 Emery-Dreifuss muscular dystrophy","volume":"101","author":"Puckelwartz","year":"2011"},{"key":"10.1016\/j.cjca.2026.01.055_bib162","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.hrthm.2012.06.038","article-title":"Arrhythmias in the muscular dystrophies","volume":"9","author":"Groh","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cjca.2026.01.055_bib163","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","article-title":"Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies","volume":"140","author":"Wahbi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib164","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4910","article-title":"Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing","volume":"7","author":"Chemello","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.cjca.2026.01.055_bib165","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.omtn.2023.04.009","article-title":"Single-swap editing for the correction of common Duchenne muscular dystrophy mutations","volume":"32","author":"Chai","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.cjca.2026.01.055_bib166","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2024.01.003","article-title":"Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy","volume":"153","author":"Mendell","year":"2024","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib167","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib168","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2026.01.055_bib169","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib178","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.pediatrneurol.2014.08.002","article-title":"Gene therapy for muscular dystrophy: moving the field forward","volume":"51","author":"Al-Zaidy","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.cjca.2026.01.055_bib179","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.nmd.2021.08.004","article-title":"The DMD gene and therapeutic approaches to restore dystrophin","volume":"31","author":"Fortunato","year":"2021","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.cjca.2026.01.055_bib180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14712598.2021.1832462","article-title":"Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy","volume":"21","author":"Schneider","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib181","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ymthe.2017.02.013","article-title":"Systemic AAV-mediated \u03b2-sarcoglycan delivery targeting cardiac and skeletal muscle ameliorates histological and functional deficits in LGMD2E mice","volume":"25","author":"Pozsgai","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib182","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41591-023-02730-9","article-title":"Gene therapy with bidridistrogene xeboparvovec for limb-girdle muscular dystrophy type 2E\/R4: phase 1\/2 trial results","volume":"30","author":"Mendell","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib183","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib184","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1089\/hum.2019.363","article-title":"Stress-induced mouse model of the cardiac manifestations of Friedreich\u2019s ataxia corrected by AAV-mediated gene therapy","volume":"31","author":"Salami","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib185","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1089\/hum.2023.020","article-title":"Identification of safe and effective intravenous dose of AAVrh.10hFXN to treat the cardiac manifestations of Friedreich\u2019s ataxia","volume":"34","author":"Munoz-Zuluaga","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib188","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.nurt.2008.08.001","article-title":"Myotonic dystrophy: therapeutic strategies for the future","volume":"5","author":"Wheeler","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cjca.2026.01.055_bib189","doi-asserted-by":"crossref","first-page":"11748","DOI":"10.1073\/pnas.0604970103","article-title":"Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy","volume":"103","author":"Kanadia","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cjca.2026.01.055_bib190","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/clc.23572","article-title":"Cardiac amyloidosis-a review of current literature for the practicing physician","volume":"44","author":"Ash","year":"2021","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cjca.2026.01.055_bib191","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.01.055_bib192","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and therapeutic approaches to cardiac amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2026.01.055_bib193","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cjca.2026.01.055_bib194","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/heartjnl-2012-301924","article-title":"Cardiac transthyretin amyloidosis","volume":"98","author":"Jason","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2026.01.055_bib195","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.cjca.2026.01.055_bib196","article-title":"High hereditary transthyretin-related amyloidosis prevalence in Crete","volume":"8","author":"Minas","year":"2022","journal-title":"Neurol Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib197","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1126836","article-title":"Prevalence estimation of ATTRv in China based on genetic databases","volume":"14","author":"Yongsheng","year":"2023","journal-title":"Front Genet"},{"key":"10.1016\/j.cjca.2026.01.055_bib198","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.01.055_bib199","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","article-title":"A review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis","volume":"9","author":"Urits","year":"2020","journal-title":"Neurol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib200","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib201","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/17460441.2024.2306843","article-title":"Vutrisiran: a new drug in the treatment landscape of hereditary transthyretin amyloid polyneuropathy","volume":"19","author":"Plant\u00e9-Bordeneuve","year":"2024","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.cjca.2026.01.055_bib202","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.01.055_bib203","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038767","article-title":"A mini-review of vutrisiran and eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"103","author":"Olatunji","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cjca.2026.01.055_bib204","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cpt.1974","article-title":"Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting N-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects","volume":"109","author":"Habtemariam","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2026.01.055_bib205","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2026.01.055_bib207","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.cjca.2026.01.055_bib208","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:12:06Z","timestamp":1778202726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":190,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0828282X26000851"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.055","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene-based Therapies for Genetic Cardiomyopathies: Molecular Medicine for Heart Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.01.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}